Approval · Notice of Compliance 17686 · 2016
IPG-RISPERIDONE: Notice of Compliance 17686
Issued January 19, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17686
- Date
- January 19, 2016
- Company
- Marcan Pharmaceuticals Inc.Ottawa, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Merger - buyout
- Canadian reference product
- RISPERDAL (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IPG-RISPERIDONE | 02359057 | Approved |
| IPG-RISPERIDONE | 02359065 | Approved |
| IPG-RISPERIDONE | 02359073 | Approved |
| IPG-RISPERIDONE | 02359081 | Approved |
| IPG-RISPERIDONE | 02359103 | Approved |
| IPG-RISPERIDONE | 02359111 | Approved |
Medicinal ingredients
- RISPERIDONE 0.25 MG per TAB
- RISPERIDONE 0.5 MG per TAB
- RISPERIDONE 1 MG per TAB
- RISPERIDONE 2 MG per TAB
- RISPERIDONE 3 MG per TAB
- RISPERIDONE 4 MG per TAB